Budesonide (200mcg) is a potent, non-halogenated glucocorticoid used primarily as an inhaled corticosteroid (ICS) for the maintenance treatment of asthma and as an oral controlled-release formulation for Crohn's disease. It has high topical anti-inflammatory potency with low systemic bioavailability due to extensive first-pass hepatic metabolism, making it a cornerstone of asthma management in the Indian context due to its favorable safety profile.
Adult: Asthma (Inhalation): 200-400 mcg twice daily or 400 mcg once daily (depending on device and severity). Maintenance: Lowest effective dose. Max: 1600 mcg/day. Crohn's (Oral): 9 mg once daily in the morning for up to 8 weeks.
Note: INHALATION: Shake well before use. For Metered-Dose Inhaler (pMDI), use with a spacer device for optimal lung deposition and to reduce oropharyngeal side effects. Rinse mouth with water and spit out after each use to prevent oral candidiasis and dysphonia. Do not exceed prescribed dose. ORAL (for Crohn's): Swallow capsule whole in the morning with a glass of water. Do not chew or crush.
Budesonide is a potent glucocorticoid receptor agonist. It diffuses across cell membranes and binds with high affinity to cytoplasmic glucocorticoid receptors. The activated receptor complex translocates to the cell nucleus, where it modulates gene transcription. It increases the synthesis of anti-inflammatory proteins (like lipocortin-1) and decreases the synthesis of pro-inflammatory mediators (such as cytokines, leukotrienes, and prostaglandins). This results in potent local anti-inflammatory, anti-edematous, and immunosuppressive effects in the respiratory mucosa or intestinal lining.
Pregnancy: Pregnancy Category C (US FDA). Adequate human data lacking. Use only if potential benefit justifies potential risk to the fetus. Inhaled corticosteroids are preferred over oral steroids for asthma management in pregnancy. Neonates exposed in utero should be monitored for hypoadrenalism.
Driving: Budesonide is unlikely to affect the ability to drive or use machines. However, if dizziness or visual disturbances occur as rare side effects, caution is advised.
| Ketoconazole, Itraconazole, Posaconazole, Voriconazole | Potent CYP3A4 inhibitors increase budesonide plasma levels significantly, risk of systemic corticosteroid effects and HPA axis suppression. | Major |
| Ritonavir, Cobicistat, Clarithromycin | Strong CYP3A4 inhibitors; co-administration is contraindicated or requires significant dose reduction and close monitoring. | Major |
| Phenytoin, Phenobarbital, Rifampicin, Carbamazepine | Potent CYP3A4 inducers decrease budesonide plasma levels, potentially reducing its efficacy. | Moderate |
| Other Corticosteroids (oral/injected) | Additive risk of HPA axis suppression and corticosteroid side effects. | Moderate |
| Diuretics (e.g., Furosemide, Hydrochlorothiazide) | Increased risk of hypokalemia. | Moderate |
Same composition (Budesonide (200mcg)), different brands: